#1
|
||||
|
||||
ÌÀËÜÒÎÔÅÐ È ÔÅÐÐÓÌ ËÅÊ
Óâàæàåìûå êîëëåãè, ïîäåëèòåñü, ïîæàëóéñòà, ñâîèìè íàáëþäåíèÿìè- íàñêîëüêî ñèëüíî ðàçëè÷àþòñÿ ïðåïàðàòû ÌÀËÜÒÎÔÅÐ è ÔÅÐÐÓÌ ËÅÊ. Îáà äëÿ âíóòðèìûøå÷íîãî ââåäåíèÿ.
Ïðîñòî ñòàëè îòìå÷àòüñÿ ïîáî÷íûå ýôôåêòû íà ìàëüòîôåð. êîòîðûõ íå íàáëþäàëîñü ó òîãî æå áîëüíîãî íà ôåððóì ëåê. È ýòî íå åäèíè÷íûé ñëó÷àé. |
#2
|
||||
|
||||
Äà íè÷åì îñîáî íå ðàçëè÷àþòñÿ, IMHO.
|
#3
|
||||
|
||||
Öèòàòà:
Íî ìàëüòîôåð ïî÷åìó-òî õóæå ïåðåíîñèòñÿ ïàöèåíòàìè.Òî åñòü çàÿâëåííûå â èíñòðóêöèè ê ïðèìåíåíèþ ïîáî÷íûå ýôôåêòû ÷àùå ïðîÿâëÿþòñÿ. |
#4
|
||||
|
||||
Öèòàòà:
|
#5
|
||||
|
||||
Öèòàòà:
|
#6
|
||||
|
||||
Öèòàòà:
|
#7
|
||||
|
||||
Öèòàòà:
Íó íå îáÿçàòåëüíî â äîìàøíèõ óñëîâèÿõ. Ïî êðàéíåé ìåðå ïåðâóþ èíúåêöèþ äåëàåì â óñëîâèÿõ ËÏÓ. Ñóòü âîïðîñà íå â ýòîì. Íî çà èíòåðåñ ê òåìå ñïàñèáî. |
|
#8
|
||||
|
||||
Öèòàòà:
|
#9
|
||||
|
||||
Öèòàòà:
ß ïðåêðàñíî çíàþ, êîëëåãà, ÷òî íåîáõîäèìîñòè â ïàðåíòåðàëüíîì ââåäåíèè ïðåïàðàòîâ æåëåçà çà ðåäêèì èñêëþ÷åíèåì íåò. Îäíàêî, è Âû, ïîëàãàþ, íå õóæå ìåíÿ çíàåòå, ÷òî ïðèäåðæèâàòüñÿ íàçíà÷åíèé ïðîôèëüíîé êëèíèêè âñå òàêè ìû äîëæíû. |
#10
|
|||
|
|||
Öèòàòà:
Êñòàòè, ÷òî çíà÷èò àìáóëàòîðíîå â/ì ââåäåíèå? Ýòî áîëüíîé ñàì ñåáå äîìà êîëåò èëè â ïîëèêëèíèêó áåãàåò? |
#11
|
||||
|
||||
Öèòàòà:
Ïàöèåíòû è â ïîëèêëèíèêó áåãàþò è ñàìè êîëÿò, äîìà. ß æ íå îá ýòîì..... Èíòåðåñóåò, â êîòîðûé ðàç ïîâòîðþñü, îïûò â ñðàâíåíèè äâóõ êîíêðåòíûõ ïðåïàðàòîâ.Âîò è âñå. |
#12
|
||||
|
||||
Öèòàòà:
Ò.å. â íåêîòîðûõ ðåêîìåíäàöèÿõ âîîáùå ðàçëè÷àþò óæå òîëüêî per os è âíóòðèâåííîå æåëåçî... À ïî òåìå ÿ óæå âûñêàçàëñÿ. Íó íå íðàâèòñÿ ìíå ìûñëü íà÷èíàòü ëå÷åíèå àíåìèé ñ ìûøå÷íîãî æåëåçà, èìåþ ïðàâî âûñêàçàòüñÿ |
#13
|
||||
|
||||
Öèòàòà:
|
#14
|
|||
|
|||
Öèòàòà:
À âîò ïðèâåò îò óâàæàåìîãî Âàäèìà Âàëåðüåâè÷à: Parenteral Iron Therapy Options Scott B. Silverstein and George M. Rodgers Parenteral iron therapy is occasionally necessary for patients intolerant or unresponsive to oral iron therapy, for receiving recombinant erythropoietin therapy, or for use in treating functional iron deficiency. There are now three parenteral iron products available: iron dextran, ferric gluconate, and iron sucrose. We summarize the advantages and disadvantages of each product, including risk of anaphylaxis and hypersensitivity, dosage regimens, and costs. The increased availability of multiple parenteral iron preparations should decrease the need to use red cell transfusions in patients with iron- eficiency anemia. American Journal of Hematology 76:74–78 (2004) Æåëàþùèì âûñûëàþ ïîëíûé òåêñò íà ìåéë |
#15
|
||||
|
||||
À âîò ïðèâåò îò óâàæàåìîãî Âàäèìà Âàëåðüåâè÷à
Áëàãîäàðþ, Âàøè ññûëêè âñåãäà èíòåðåñíû. |